Recent Developments in Immuno-oncology: Biomarkers, Pan-tumor Studies, Novel Treatment Combinations, and the Management of Adverse Events

Target Audience

This initiative is designed to meet the educational needs of oncologists, oncology pharmacists, oncology nurses, and other healthcare professionals and teams involved in the management of patients with cancer who are treated or eligible for treatment with immunotherapy.

Program Overview

This whiteboard preceptorship will cover the diagnosis, treatment, and management of patients with cancer who are treated or eligible for treatment with immunotherapy.

Learning Objectives

Upon completion of the program, attendees should be able to:

Review potential predictive or prognostic immune-related biomarkers and biomarker testing methodologies
Examine clinical evidence supporting the use of immune checkpoint inhibitors both as monotherapy and combination with chemotherapy or other immune agents.
Recognize and manage immune-related adverse events (irAEs) associated with the use of checkpoint inhibitors
Explain patient-centered shared decision-making approaches aimed at optimizing cancer care and survivorship and the roles of the multidisciplinary team members in diagnosing and managing irAEs.